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A Real-Time Fluorogenic Phospholipase A2 Assay
for Biochemical and Cellular Activity Measurements
invasiveness and reduces the sensitivity of cancer cells
to chemotherapy [3].
The majority of the PLA2 enzymes fall into four catego-
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1Department of Medicinal Chemistry ries. First, the so-called secreted forms, or sPLA2s, com-
prise more than nine small molecular-weight (14 kDa)The University of Utah
419 Wakara Way, Suite 205 isozymes represented by groups I, II, V, and X [4]. Sec-
ond, the cytosolic PLA2 (cPLA2) isozymes include at leastSalt Lake City, Utah 84108
2 Center for Cell Signaling three 85 kDa group IV enzymes [5]. Third, the intracellular
PLA2 (iPLA2) isozyme is an 80 kDa calcium-independent420 Wakara Way, Suite 360
Salt Lake City, Utah 84108 cPLA2 of group VI [6]. Finally, there are a number of
other PLA2 families with single isoforms; an example is3 Department of Biology
Utah State University platelet-activating factor acetyl hydrolase, which hydro-
lyzes the sn-2 acetate but is not involved in eicosanoid5305 University Boulevard
Logan, Utah 84322 signaling events [7]. The categorization of PLA2 iso-
zymes depends on molecular weight, biological source,
calcium requirement, and other biochemical properties.
The four major types may be distinguished by group-Summary
specific assays capable of measuring hydrolysis with
subnanogram quantities of enzyme [8]. Indeed, sPLA2A fluorogenic analog of the PLA2 substrate PC, named
forms can be either intracellular or secreted, are widelyDabcyl-BODIPY-PC, or simply DBPC, was synthesized
found in many mammalian tissues, and are common lyticwith a fluorescence quencher (Dabcyl, 4-[(4-[N,N-
components of insect and snake venoms. The sPLA2dimethylamino]phenyl)azo]benzoic acid) in the sn-1
isozymes bear no sequence similarity with cPLA2 [9],acyl chain and a BODIPY fluor in the sn-2 acyl chain.
which exhibits an overwhelming preference for phos-DBPC was recognized by sPLA2 from each of the four
pholipids that contain arachidonic acid (AA) in the sn-2sources examined (bee venom, human synovial fluid,
position [10–12].cobra venom, and bovine pancreas). A dramatic and
cPLA2s and sPLA2s are considered signaling PLA2s,quantifiable fluorescence enhancement of DBPC oc-
which regulate the stimulus-induced arachidonate me-curred upon phospholipase digestion both in the pres-
tabolism, which is linked in turn to the production ofence and absence of excess PC. Both real-time and
bioactive eicosanoids. iPLA2 has a major role in the re-endpoint assays for PLA2 were sensitive, consistent,
modeling of phospholipids [6], and recent evidence sug-and rapid. Thus, DBPC can be used as a sensitive
gests that it can also participate in lipid signaling. Groupfluorogenic probe for in vitro high-throughput screen-
IIA PLA2 has antibacterial activity and also functionsing assays for PLA2 activation and inhibition and would
as a modifier of tumor multiplicity [13, 14]. Both iPLA2expedite studies of PLA2 in cellular signaling, in vitro
inhibition and depletion of human iPLA2 demonstratescreening for drug discovery, and subcellular localiza-
that this enzyme plays a key role in lymphocyte prolifera-tion of enzyme activity.
tion [15]. In apoptosis research, the membrane lipids of
the apoptotic and damaged cells are preferred sub-
Introduction strates for the PLA2s. A number of extracellular and
intracellular PLA2 isozymes are substrates of caspasesPhospholipase A2 (PLA2) enzymes comprise a growing [16–18].
family of enzymes widely expressed in insects, reptiles, The PLA2 family of isozymes is complex, and as newand mammals. The isozymes differ in substrate specific- isozymes are discovered, it becomes apparent that
ity, cofactor requirements, subcellular locations, and some functions were incorrectly correlated with a partic-
physiological functions [1]. All PLA2 isozymes cleave the ular isoform. For example, the recent discovery of other
sn-2 acyl chain of a glycerophospholipid to produce two small molecular-weight PLA2s has drawn attention topotential lipid mediators: a free fatty acid and a lyso- some of the functions that were previously attributed
phospholipid. For example, the cleavage of phosphati- to group IIA PLA2s. Continued discovery of new PLA2
dylcholine (PC) to lyso-PC affords a chemoattractant isoforms and development of a systematic understand-
for circulating monocytes [2]. Arachidonate, frequently ing of this enzyme family is important for the understand-
found in the sn-2 position of mammalian phospholipids ing of disease pathologies and for the success of basic
and all mammalian phosphoinositides, is the key eicosa- research. For the identification of active enzymes, sev-
noid precursor for the production of thromboxanes, eral analytical approaches are employed. Most methods
prostaglandins, and leukotrienes. Recently, phospholi- of measuring enzyme activity utilize extraction and chro-
pase D and several PLA2 isozymes have been implicated matographic separation of end products. These classi-
in the production of LPA, a potent mitogen that is over- cal endpoint assays involve radio-HPLC or radio-TLC
produced in ovarian cancer and that stimulates tumor separation of radiolabeled lipids [19, 20]. Endpoint
assays do not permit continuous monitoring of phos-
pholipase activation in live cells and cannot be readily4 Correspondence: gprestwich@pharm.utah.edu
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Fmoc deprotection had occurred. Condensation of the
primary amine of 5 with an activated ester containing
the Dabcyl chromophore gave the sn-1 acyl derivative
with the quencher installed. Finally, the t-Boc was re-
moved to give intermediate amine 6, which was con-
densed with BODIPY-succinimidyl ester to give the final
product DBPC (7).
A molecular model of DBPC was constructed and
analyzed with Cambridge Software Chem3D Pro. After
energy minimization of DBPC, the conformation space
was explored by molecular dynamics. Across a wide
array of structures, the distance of BODIPY and Dabcyl
(measured by the distance of F69 on BODIPY to N40
on Dabcyl) was in the range of 6–40 A˚. Figure 3 illustrates
two of the most stable conformations of DBPC, one ofFigure 1. Principle of the Fluorogenic, or “Fluorescence Dequench-
ing,” Assay for PLA2 which has the BODIPY fluorophore partially pi-stacked
The scissile ester bond is indicated by the open arrow. with the Dabcyl chromophore.
The structure of DBPC is analogous to the structure of
bis-BODIPY PC (BBPC, 8) (see Figure 2), a commercially
applied to high-throughput screening for kinetic analysis available material. In order to compare DBPC (7) and
or inhibitor discovery. The internally pi-stacked bis- BBPC (8) as fluorogenic substrates, we performed end-
BODIPY phosphatidylcholine (BBPC), a commercially point hydrolysis experiments by using the commercially
available substrate for phospholipase A enzyme activity, available PLA2 isozyme from bee venom. The digestion
has been used in continuous assays to monitor the re- of DBPC with Apis mellifera (bee) venom PLA2 produced
sponses of neutrophils [21]. However, BBPC applica- TLC spots for the fluorescent free fatty acid and a red-
tions were limited because incomplete intramolecular dish colored Dabcyl lyso-PC spot (our unpublished
self-quenching of the fluorophores led to high back- data). After 1.5 hr of digestion of DBPC by bee venom
ground fluorescence with this probe. Moreover, BBPC PLA2, the fluorescence enhancement approached 25-
assays show low sensitivity because only a modest en- fold relative to the unhydrolyzed substrate (Figure 4A).
hancement of fluorescence occurred upon hydrolysis. In contrast, digestion of BBPC by bee venom PLA2 for
We now present the synthesis as well as the in vitro the same time period resulted in a modest 2.5-fold fluo-
and in situ evaluation of a novel PC analog that allows rescence enhancement. Under these experimental con-
monitoring of PLA2 activity via a sensitive fluorogenic ditions, saturation was achieved at approximately 1.0
assay. The key concept is that of “fluorescence de- units (U) of bee venom PLA2. The enhancement was
quenching” (Figure 1), in which the internal quenching largely due to the much lower intrinsic fluorescence of
is provided by a nonfluorescent energy absorber rather the DBPC substrate relative to that of BBPC.
than by the stacking of identical planar fluorophores Next, the substrate specificity of DBPC by sPLA2 iso-
as in BBPC. This new analog, Dabcyl-BODIPY-PC, or zymes from a variety of biological sources was deter-
simply DBPC, has very low background fluorescence mined with a fluorescence microtiter plate reader. DBPC
with distinct enhancement of the fluorescent signal was a substrate for each of the four sPLA2 sources
when it is cleaved in both PS and cholesterol-PG-PC studied: bee venom, human synovial fluid, bovine pan-
liposomes. This finding suggests its utility for in vitro creatic fluid, and Naja naja (cobra) venom (Figure 4B);
screening for inhibitors of PLA2. Finally, DBPC hydrolysis PS liposomes containing 10% of each fluorogenic com-
in the plasma membranes of canine kidney cells was pound were used. Among the four enzymes, bee venom
observed after the induction of cPLA2 activity. This find- and human synovial sPLA2 were the most favorable en-
ing provides a proof-of-concept for the development of zymes for hydrolysis of DBPC.
a real-time cell-based assay for PLA2 activity. Although DBPC, when applied to cell-based assays,
may be subject to digestion by both PLA1 and PLA2,
Results specific inhibitors can be used to differentiate the en-
zyme activities. For proof-of-concept studies, bee
The synthesis of 1-O-(6-Dabcyl-aminohexanoyl)-2-O-(6- venom sPLA2 was used to measure the kinetics of DBPC
[12-BODIPY-dodecanoyl]amino-hexanoyl)-sn-3-glycer- hydrolysis as well as inhibition with a specific sPLA2
ylphosphatidylcholine (DBPC) (7) was carried out as inhibitor, TEPC [23]. The fluorescence enhancement of
shown in Figure 2. First, chiral p-methoxybenzyl (PMB)- the phospholipase reaction was recorded every 40 s in
protected glycerol was sequentially esterified with Fmoc the absence of inhibitor, as well as for each of three
(9-fluorenylmethoxycarbonyl) and t-Boc (t-butoxycar- inhibitor concentrations for a period of at least 20 min.
bonyl)-protected 6-aminohexanoic acids in the sn-1 and The initial velocity was calculated from the first 2 min
sn-2 positions, respectively, to give diester 2. The PMB of the enzymatic reaction. A Lineweaver-Burk double-
protecting group was then oxidatively removed, and reciprocal plot was prepared from the kinetic data, and
intermediate alcohol 3 was phosphorylated with 2-chloro- a KM value of 18.0 M for DBPC was calculated (Figure
2-oxo-1,3,2-dioxaphospholane [22] to give cyclic phos- 5B). A Dixon plot (our unpublished data) replotting the
phate 4. Reacting intermediate 4 with trimethylamine at slopes of the double-reciprocal lines for each inhibitor
concentration afforded a KI value of 0.9 M for TEPC in60C gave the PC derivative 5, in which concomitant
Fluorogenic PLA2 Assay
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Figure 2. Synthesis of the Fluorogenic Substrate
Reaction conditions: (a) FmocNH(CH2)5COOH, DCC, DMAP, CH2Cl2, 4oC, overnight; (b) t-BocNH(CH2)5COOH, DCC, DMAP, CH2Cl2, r.t. overnight;
(c) DDQ, CH2Cl2:H2O (100:1), r.t., overnight; (d) (CH2)2PO3Cl, Et(iPr)2N, toluene, r.t., overnight; (e) (CH3)3N, CH3CN, 60oC, 20 hr; (f) Dabcyl-SE,
DMF/TEAB (0.25 M, pH 8.0) (1:1), r.t., 5 hr; (g) TFA/CH2Cl2; (h) BODIPY-SE, DMF/TEAB (0.25 M, pH 8.0) (1:1), r.t., overnight.
this assay system. This result is comparable to the KI tored in real time after the addition of aliquots of four
concentrations of bee venom sPLA2. It is noteworthyvalue of 2 M reported for cobra venom sPLA2. To show
that our DBPC assay system would also be applicable that both BBPC and DBPC were hydrolyzed in the pres-
ence of a 2.5-fold excess of competing PC in theseto human sPLA2, we also examined the kinetic behavior
of human synovial sPLA2 with DBPC as well as its inhibi- assays. For BBPC, a 25% enhancement of fluorescence
(over a high background) was observed at 35 min withtion by TEPC. A KM value of 14.2 M was obtained for
the human synovial sPLA2, and TEPC showed an IC50 0.1 mg/ml sPLA2, whereas with DBPC, enhancement
greater than 300% was observed under the same condi-value below 2M for this enzyme (our unpublished data).
Next, we performed sPLA2 assays in liposomes com- tions, with much lower background fluorescence (Figure
5A). Furthermore, DBPC-containing cholesterol-PG-PCposed of cholesterol, PG, and 1-palmitoyl-2-oleoyl-
phosphatidylcholine (POPC) (1:1:4 wt:wt:wt) and 20 wt% liposomes were examined by confocal fluorescence mi-
croscopy in the absence (inset) and presence of cobraof BBPC or 20 wt% of DBPC in the liposome. These
liposomes were sonicated and sized, and aliquots were venom sPLA2 (Figure 6).
Finally, a cell-based assay was performed with a bra-placed on microtiter plates and analyzed with a fluores-
cence plate reader. Fluorescence changes were moni- dykinin (BK)-inducible canine kidney cell line (MDCK-
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Figure 3. Two Maximally Stable DBPC Structures Obtained by En-
ergy Minimization of Discrete Conformations after Molecular Dy-
namics Figure 4. Hydrolysis of DBPC by sPLA2s
(A) F69-N40: 6.05 A˚. (A) Fluorescence increase after hydrolysis of 8.86M (final volume
(B) F69-N40: 9.25 A˚. 100 l) of either DBPC (7, solid bars) and BBPC (8, dotted bars) by
bee venom sPLA2 for 1.5 hr. Fluorescence enhancement is com-
pared at different amounts of sPLA2 from 0 to 5 U.
(B) Kinetic curves for digestion of DBPC 7 (4.84 M in 100 l finalD1 cells) [24]. Cytosolic PLA2 accounts for the majority of
volume) with four secreted isozymes: human synovial sPLA2 (0.1AA released from the sn-2 position of plasma-membrane
U, squares), bee venom (0.1 U, up triangles), bovine pancreas (1.0PC. Thus, cells were treated with DBPC, which was
U, diamonds), and cobra venom sPLA2 (1.0 U, down triangles).passively incorporated into MDCK-D1 cell membranes.
Cells were left without stimulation or were stimulated
with 1 M BK and monitored by confocal microscopy cher). We refer to fluorogenic assays in the latter cate-
gory as “fluorescence dequenching” assays to distin-for 30 min. Figure 7 shows time zero and t  3 min
images for the unstimulated control cells (Figures 7A guish them from fluorogenic assays in which a nonfluo-
rescent chromophore becomes fluorescent when it isand 7B) and the BK-stimulated cells (Figures 7C and
7D). Cleavage of the sn-2 acyl chain by induced cPLA2 released from a substrate. An example of this type of
fluorogenic assay is the liberation of fluorescein by areleased the fluorescent fatty acid, which appeared to
remain predominately localized in the plasma mem- phosphatidylinositol-specific phospholipase C [25]. Flu-
orescence dequenching assays are desirable for real-brane as a result of the hydrophobicity of the BODIPY
fluorophore. No such fluorescence was observed in the time monitoring of enzymatic reactions in microtiter
plate assays and in cell-based observations becauseplasma membrane of unstimulated cells.
they do not require isolation and separation of enzymatic
products. Such applications have been applied to theDiscussion
monitoring of specific nucleic acid hybridizations with
molecular beacons [26], for -glutamyl hydrolase [27],Because of high sensitivity and low cellular toxicity, the
utilization of biochemical and biological assays based for DNA ligase [28], and at the completion of the work
described herein, for PLA2 [29–31].on fluorescence has increased dramatically. One of
these methods employs fluorescence energy transfer The use of DBPC as a detection system for PLA2 best
demonstrates the principle of fluorescence dequench-between two fluorophores or between a fluorophore and
a nonfluorescent chromophore (fluorescence quen- ing. In an analogous fashion to BBPC, the Dabcyl group
Fluorogenic PLA2 Assay
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Figure 6. Fluorescence Micrograph of DBPC
Fluorescence micrograph of DBPC (20 wt%) in cholesterol-PG-PC
(1:1:4) liposomes after 25 min treatment with 1 wt% cobra venom
sPLA2. The inset shows unstimulated liposomes. Scale bar 50 m.
Figure 5. Kinetic Study of DBPC with Bee Venom sPLA2
(A) Kinetics of fluorescence intensity increase of BBPC (20 wt%) or
DBPC (20 wt%) in cholesterol-PG-PC (1:1:4) liposomes treated with
0.025 mg/ml or 0.1 mg/ml bee venom sPLA2. Key: DBPC, 0.1 mg/
ml PLA2 (squares); DBPC, 0.025 mg/ml PLA2 (diamonds); BBPC, 0.1
mg/ml PLA2 (circles); BBPC, 0.025 mg/ml PLA2 (x). For all data,
background controls without PLA2 were subtracted.
(B) Double reciprocal plot of the enzymatic reaction of bee venom
sPLA2 (0.05 U per 100 l reaction) and DBPC with three different
concentrations of the sPLA2 inhibitor, TEPC. The calculated KM for
DBPC with the bee venom enzyme was 18.0 M (our unpublished
data). A Dixon plot of the slopes for three concentrations of TEPC
Figure 7. Activity of cPLA2 in MDCK-D1 Cellsgave a KI value of 0.9 M, compared with a KI value of 2 M for
Activity of cPLA2 in MDCK-D1 cells at t 0 and 3 min in unstimulatedcobra venom [33].
(A and B) and BK-stimulated (C and D) cells. Hydrolysis was ob-
served at the plasma membrane of cells with induced cPLA2 activity.
of DBPC is in close proximity to and potentially pi-
stacked with the BODIPY fluorophore [32]. Dabcyl can either a PLA2 or PLA2 isozyme, the quencher and fluoro-
phore become separated (Figure 1) and the BODIPYabsorb a photon emitted by an excited BODIPY fluor
but cannot fluoresce; it thus diminishes the background emission is no longer quenched. Figure 3 illustrates two
of the most stable DBPC conformations, one of whichfluorescence of the substrate via intramolecular energy
transfer. The background fluorescence of the DBPC has the BODIPY fluorophore nearly pi-stacked with the
Dabcyl chromophore. The optimized molecular modelsubstrate is thus substantially diminished relative to the
pi-stacked two-fluor BBPC substrate. When the intra- of DBPC was obtained with a favorable BODPY-Dabcyl
distance for resonance energy transfer. The usual dis-molecular relationship in DBPC is disrupted, e.g., by
hydrolysis of either the sn-1 or the sn-2 acyl chain by tance for a fluorescence acceptor to interact with the
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donor fluorophore is 10–100 A˚. In the minimized models, somes), it validates the potential for DBPC as an sPLA2
substrate both in vitro and in situ.the distance between the fluorescence donor and ac-
ceptor is in the low end of this range and explains the Finally, we tested the utility of DBPC for the visualiza-
tion of PLA2 activity in MDCK-D1 cells. Insel and cowork-efficient intramolecular fluorescence quenching ob-
served. ers have used this cell line to exhaustively analyze BK-
mediated activation of AA release and phosphoinositideIn our studies, the commercial two-fluor substrate
BBPC was inferior to DBPC. BBPC uses one fluorophore hydrolysis [35]. Both the release of arachidonate from
PC and phosphoinositide hydrolysis occur in responseto quench another fluorophore, which contributes to a
much higher background. In elegant work, Farber and to the B1 and B2 receptor agonist BK. We observed
that release of the fluorescent BODIPY-labeled fatty acidcoworkers [30] reported monitoring PLA2 activity in ze-
brafish embryos by using a new fluorescence dequench- from DBPC was detectable in less than 1 min (our unpub-
lished data) after treatment of cells with 1 M BK anding probe similar to DBPC. This report, which appeared
after we had completed the synthesis and evaluation of was sustained for more than 20 min. Importantly, most
of the fluorescence increase was observed in the plasmaDBPC, employed a dinitrophenyl quencher in a modified
phosphatidylethanolamine head group and a very short membrane of the stimulated cells, suggesting that the
BODIPY-fatty acid that was released remained in thesn-2 acyl chain. This probe had the advantage that PLA1
activity would not interfere with the fluorescence inten- membrane during the BK stimulation (Figure 7). These
results differ significantly from those observed forsity but lacked convincing mimicry of the PC substrate.
Detailed kinetic and in vitro enzymatic data were lacking MDCK-D1 cells loaded with BBPC prior to BK stimula-
tion. With BBPC-loaded cells, the majority of the fluores-in this report. A modified BBPC with two different fluors
was also described, but background and differentiation cence increase was observed in intracellular bilayers
(our unpublished data). Because both the fatty acid andof PLA1 and PLA2 activity were still not achievable. The
approach of incorporating both the quencher and the the lyso-PC product contain identical BODIPY fluors,
this result cannot be readily interpreted because thefluor in different acyl chains, a synthetically more difficult
challenge, had not yet been previously reported. source of the fluorescence remains cryptic. These ob-
servations appear to suggest that DBPC accumulatesAs described above, DBPC was recognized with sig-
nificant signal-to-noise ratio by each of the four sPLA2 primarily in the plasma membrane, whereas BBPC accu-
mulates both in the plasma membrane and in other intra-isozymes examined, with the result that bee venom and
human synovial PLA2 showed the most favorable activity cellular bilayers. Taken together, our results indicate
that DBPC, in addition to providing a superior probe forfor this PC analog. Moreover, the amount of the human
synovial enzyme used was only about 0.5 ng, suggesting in vitro measurements of the activity and inhibition of
PLA2, serves as a superior probe for subcellular localiza-that DBPC would be an excellent substrate for continu-
ous monitoring of the activity of this enzyme in an assay tion of PLA2 activity in cells.
for the discovery of therapeutic agents targeted at joint
inflammation. Although the sensitivity of the fluorogenic
Significanceassay was sensitive enough to permit the use of DBPC
for cobra venom and bovine pancreatic sPLA2 reactions,
A fluorogenic analog of the phospholipase A substratethere was an order of magnitude lower efficiency in
PC was prepared by chemical synthesis. This analog,the processing of DBPC as a substrate by these two
named DBPC, featured a Dabcyl quencher moiety inenzymes than by bee venom and human sPLA2s. Given
the sn-1 acyl chain and a BODIPY fluorescent moietythe known substrate selectivities of different PLA2 en-
in the sn-2 acyl chain. The intramolecular proximityzymes, the differential activity of four sPLA2 isozymes
of the Dabcyl and BODIPY chromophores resulted intoward DBPC was not unexpected.
effective quenching of BODIPY fluorescence by intra-DBPC is also susceptible to other enzymatic reac-
molecular energy transfer in the DBPC substrate. Hy-tions. Thus, we used an isozyme-specific inhibitor to
drolysis of DBPC by PLA2 released the sn-2 acyl-linkedconfirm that the fluorogenic reaction indeed measured
BODIPY moiety, and fluorescence increased as a func-the fluorescence increase due to PLA2 activity. Thus,
tion of the extent of lipase activity. This “fluorescencethe kinetics of hydrolysis of DBPC by bee venom and
dequenching” assay occurred with approximately 25-human sPLA2 were examined with increasing amounts
fold enhancement of fluorescence at a moderate levelof TEPC as an inhibitor (Figure 6). TEPC is a competitive,
of hydrolysis of DBPC by bee venom PLA2 in PS lipo-reversible inhibitor of sPLA2, with an IC50 value of 2 M
somes and a 3-fold enhancement in cholesterol-PG-for cobra venom sPLA2 [33, 34]. The KI value of 0.9 M
PC liposomes. The large fluorescence increase wasfor inhibition by TEPC of the hydrolysis of DBPC by bee
clearly due to the low intrinsic background of the sub-venom sPLA2 was fully consistent with the fluorescence
strate that normally exists in a fluorescence-quenchedincrease being attributable to hydrolysis of the
state. The substrate specificity of DBPC was examinedquenched PC analog by sPLA2.
against commercially available sPLA2 isozymes. BeeThe hydrolysis of DBPC in cholesterol-PG-PC lipo-
venom sPLA2 and human synovial sPLA2 were the mostsomes as shown in Figures 5A and 6 has two important
favorable enzymes for DBPC hydrolysis, but cPLA2 ac-implications for this study. First, it demonstrates that
tivity in BK-induced canine kidney cells also hy-hydrolysis of the quencher-fluor modified PC analog can
drolyzed DBPC in the plasma membrane, as visualizedoccur in a 2.5-fold excess of competing unmodified PC.
by confocal microscopy. The feasibility of using thisAlthough this lowers the net enhancement measured
(25-fold in PS liposomes versus 3-fold in PG-PC lipo- probe for in vitro inhibition assays in microtiter plates
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for an additional 24 hr. The solvent was removed in vacuo, and thewas demonstrated by measurement of the real-time
residue was used without further purification.kinetic behavior of DBPC and its inhibition by the spe-
1-O-(6-Aminohexanoyl)-2-O-(6-t-Boc-Aminohexanoyl)-cific sPLA2 inhibitor TEPC. DBPC is thus a sensitive sn-Glyceryl Phosphatidylcholine (5)
probe for a continuous fluorogenic assay applicable Crude compound 4 was dissolved in 2 ml of CH3CN and cooled
to both in vitro and cell-based in situ screening assays to 78C. Then, (CH3)3N was cooled on ice, and 0.5 ml of (CH3)3N
was poured into the reaction mixture [22]. The reaction was stirredfor PLA2 activators and inhibitors.
at 60C–65C for 20 hr under a condenser charged with dry ice/
acetone. Solvents were removed in vacuo, and an unsuccessful
Experimental Procedures attempt was made to purify the crude material on SiO2 by elution
with CH2Cl2:MeOH:H2O (10:5:1). In the final procedure, the crude
PC derivative was used without further purification. The 1H NMRSynthesis of Fluorogenic Substrate
indicated that the Fmoc group had also been removed during the1-O-(6-Fmoc Aminohexanoyl)-3-O-
conversion of the cyclic phosphate to the phosphocholine head(p-Methoxybenzyl)-sn-Glycerol (1)
group.PMB-protected glycerol [36, 37] was reacted with 3.68 g of Fmoc-
1-O-(6-Dabcyl-Aminohexanoyl)-2-O-(6-Aminohexanoyl)-protected 6-aminohexanoic acid in the presence of dicyclohexylcar-
sn-Glyceryl Phosphatidylcholine (6)bodiimide (DCC) (2.33 g) and 4-N,N-dimethylaminopyridine (DMAP;
Compound 5 (crude, 100 mg) was dissolved in 0.25 M triethylamon-140 mg) in CH2Cl2 at 4C. TLC analysis indicated that the reaction
ium bicarbonate (TEAB) (4 ml), and 20 mg of Dabcyl-SE was added.was complete after 12 hr. The reaction mixture was filtered, and
After overnight reaction, TLC showed a new red spot at Rf  0.3CH2Cl2 was evaporated in vacuo. The residue was dissolved in ethyl
(MeOH:CHCl3:H2O, 10:1:1). The mixed solvents were concentratedacetate (EtOAc) and was filtered again. The condensed residual
by a stream of air. The reaction residue was dissolved in MeOH:mixture was chromatographed twice on SiO2, and elution with 20%
CHCl3:H2O (10:1:1) and purified on SiO2 to give 15 mg of derivativeEtOAc in dichloromethane gave a TLC-homogeneous product in
6. 1H NMR (CDCl3):  7.92–7.78 (m, 6H, Dabcyl), 6.73 (J  8.6 Hz, d,60% yield. Rf (50% EtOAc-hexane): 0.69. 1H NMR (CDCl3):  7.76
2H, Dabcyl), 5.20–5.10 (m, 1H), 4.40–3.85 (m, 6H), 3.68–3.45 (m, 2H),(J  7.9 Hz, d, 2H, Fmoc), 7.58 (J  7.3 Hz, d, 2H, Fmoc), 7.39 (J 
3.44–3.36 (m, 2H), 3.28–3.10 (m, 11H), 3.10–2.96 (m, 8H), 2.37–2.207.9 Hz, t, 2H, Fmoc), 7.30 (J  7.9 Hz, t, 2H, Fmoc), 7.21 (J  9.2
(m, 4H), 1.70–1.15 (m, 21H) ppm. 31P NMR:  0.5 ppm. HRMS (FAB):Hz, d, 2H, PMB), 6.85 (J  8.6 Hz, d, 2H, PMB), 4.99–4.87 (m, 1H),
calculated for C40H64N6O11PNa	 (M  H 	 Na	), 857.4175; found,4.46 (s, 2H, CH2O), 4.38 (J  6.1 Hz, d, 2H, Fmoc), 4.26–4.05 (m,
857.4214.2H), 4.05–3.93 (m, 1H), 3.75 (s, 3H, PMB), 3.54–3.36 (m, 2H), 3.23–3.07
The compound was further treated with TFA (2 ml TFA:2 ml(m, 2H), 2.41–2.25 (m, 2H), 1.71–1.54 (m, 2H), 1.54–1.41 (m, 2H),
CH2Cl2). The solution immediately turned dark red upon the addition1.40–1.20 (m, 2H) ppm. HRMS (FAB): calculated for C32H37NO7Na	
of TFA. After 2 hr, a single red spot appeared at Rf  0.16 (MeOH:(M 	 Na	), 570.2458; found, 570.2488.
CHCl3:H2O, 10:1:1). TFA and CH2Cl2 were removed in vacuo, and the1-O-(6-Fmoc Aminohexanoyl)-2-O-(6-t-Boc-Aminohexanoyl)-
reddish residue was washed several times with ether to remove3-O-(p-Methoxybenzyl)-sn-Glycerol (2)
traces of TFA. The amine was used without further purification.Compound 1 (2.06 g) was stirred with 1.2 equivalents of t-Boc-6-
HRMS (FAB): calculated for C35H56N6O9P	 (M 	 Na	), 735.3833;aminohexanoic acid, 1.2 equivalents of DCC, and 0.1 equivalents
found, 735.3828.of DMAP in CH2Cl2 for 48 hr at 4C. The reaction was stopped by
1-O-(6-Dabcyl-Aminohexanoyl)-2-O-(6-(12-BODIPY-filtration of the dicyclohexylurea byproduct, and the crude mixture
Dodecanoyl)Aminohexanoyl)-sn-Glycerylwas purified on SiO2 by elution with 50% EtOAc-hexane. The unre-
Phosphatidylcholine (7)acted 1 was recovered, and 1.6 g of homogeneous diacyl derivative
Compound 6 (9.1 mg) was reacted with 8 mg of BODIPY-SE for 122 was obtained (73% yield). Rf (50% EtOAc-hexane): 0.83. 1H NMR
hr at r.t.; TLC showed a major reddish and fluorescent spot at Rf (CDCl3):  7.78 (J  8.5 Hz, d, 2H, Fmoc), 7.60 (J  8.5 Hz, d, 2H,
0.3 (MeOH:CHCl3:H2O, 10:1:1). The compound was purified on SiO2Fmoc), 7.39 (J  8.0 Hz, t, 2H, Fmoc), 7.31 (J  8.5 Hz, t, 2H, Fmoc),
to give 2.8 mg of DBPC (7). 1H NMR (CDCl3):  7.99 (J  8.0 Hz, d,7.22 (J  6.1 Hz, d, 2H, PMB), 6.86 (J  6.6 Hz, d, 2H, PMB), 5.29-
2H, Dabcyl), 7.90–7.78 (m, 6H, Dabcyl), 7.05 (s, 1H, BODIPY), 6.955.17 (m, 1H), 4.50–4.28 (m, 5H), 4.28–4.05 (m, 2H), 3.79 (s, 3H, OCH3,
(J  5.5 Hz, d, 2H, BODIPY), 6.74 (J  9.2 Hz, d, 2H, Dabcyl), 6.26PMB), 3.54 (J  5.2 Hz, d, 2H), 3.26–3.02 (m, 4H), 2.37–2.21 (m, 4H),
(J  6.2 Hz, t, 2H, BODIPY), 5.28–5.15 (m, 1H), 4.42–3.96 (m, 6H),1.69–1.57 (m, 4H), 1.58–1.30 (m, 17H) ppm. HRMS (FAB): calculated
3.70–3.56 (m, 2H), 3.45 (s, 9H, -N(CH3)3), 3.30–3.10 (m, 4H), 3.08 (s,for C43H56N2O10Na	 (M 	 Na	), 783.3818; found, 783.3790.
6H, N(CH3)2), 3.03, 2.98 (J  7.4 Hz, dt, 4H), 2.40–2.24 (m, 6H),1-O-(6-Fmoc Aminohexanoyl)-2-O-(6-t-Boc-
2.16–2.08 (m, 4H), 1.90–1.80 (m, 29H). 31P NMR:  0.5 ppm. HRMSAminohexanoyl)-sn-Glycerol (3)
(MALDI): calculated for C58H87BF2N8O11P	: 1135.6323; found,Compound 2 (400 mg) and 2,3-dichloro-5,6-dicyano-1,4-benzoqui-
1135.6393.none (DDQ) (155 mg) were dissolved in wet (1% v/v) CH2Cl2, and
the yellowish solution immediately turned green. After the solution
was stirred overnight at room temperature (r.t.), TLC indicated that TLC Analysis of DBPC and BBPC Cleavage by PLA2
the reaction was complete. The reaction was diluted with CH2Cl2, Aliquots (2 g each) of DBPC and BBPC (Molecular Probes) were
and 10 ml of water was added. The water phase was extracted dissolved into 50l buffer (100 mM Tris [pH 8.0 for bovine pancreatic
with 3 
 15 ml of CH2Cl2. The combined organic extracts were sPLA2 or pH 8.9 for bee venom sPLA2]) and sonicated three times
concentrated and purified on SiO2 with 66% EtOAc-hexane. A pale at intervals of 1 min. Then PLA2 (1 U) was added to the buffer, and
yellow oil (240.5 mg) was obtained with a yield of 71.4%. Rf (60% the reaction was incubated at either 25C (bee venom sPLA2) or
EtOAc-hexane): 0.39. 1H NMR (CDCl3):  7.76 (J  7.9 Hz, d, 2H, 37C (bovine pancreatic sPLA2). Hydrolysis was monitored by TLC
Fmoc), 7.59 (J 7.9 Hz, d, 2H, Fmoc), 7.40 (J 8.5 Hz, t, 2H, Fmoc), (MeOH:CHCl3:H2O, 10:1:1).
7.32 (J  7.9 Hz, t, 2H, Fmoc), 5.15–5.06 (m, 1H), 4.24–4.30 (m, 3H),
4.30–4.15 (m, 2H), 3.78–3.65 (m, 2H), 3.23–2.98 (m, 4H), 2.40–2.22
(m, 4H), 1.72–1.55 (m, 4H), 1.55–1.25 (m, 17H). HRMS (FAB): calcu- Molecular Modeling
The structure of DBPC was constructed in ChemDraw Ultra 6.0, andlated for C35H48N2O9Na	 (M 	 Na	), 663.3245; found, 663.3289.
1-O-(6-Fmoc Aminohexanoyl)-2-O-(6-t-Boc-Aminohexanoyl)- the molecular model was obtained by going to “get 3D model”
under the “scripts” menu. The model was first energy minimized by3-O-(2-Chloro-2-Oxo-1,3,2-Dioxaphosphalyl)-sn-Glycerol (4)
Under an atmosphere of Ar, compound 3 (315 mg) was dissolved molecular mechanics (MM2 algorithm) in Chem3D 5.0. Molecular
dynamics (MM2) was then carried out at a step interval of 2.0 fsin 15 ml of toluene, and then diisopropylethyl amine (102.7 l) was
added. The solution turned yellow. Then, 2-chloro-2-oxo-1,3,2-diox- and a target temperature of 298K. The conformations after each
10 ps were energy minimized, and these local energy-minimizedaphospholane (54.2 l) [22] was added, and the reaction solution
turned brown. The reaction was stirred 24 hr, another aliquot of structures were compared in terms of total energy and the distance
between BODIPY (F69) and Dabcyl (N40).phosphorylation reagent was added, and the reaction was stirred
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Preparation of Phosphatidylserine (PS) Liposomes Cancer Society for an award (to D.B.D.). We are grateful to Mr. D.
Johnson (Utah State University, Logan, Utah) for supporting experi-and Fluorogenic Enzyme Assay
DBPC or BBPC was combined with PS (bovine brain, 98% purity, mental work and to Prof. P. Insel (University of California, San Diego)
for the MDCK-D1 cell line. We also thank Prof. E. Dennis (UniversitySigma Chemical Co. St. Louis, MO) (1:9) in CHCl3 and the liposomes
of DBPC/PS and BBPC/PS (80-100 M) were prepared as described of California, San Diego), Dr. D.-Y. Suh (University of Utah) for helpful
discussions, and Dr. C. Amann for synthesis of BODIPY-SE.[21]. In each well of a 96-well plate with a non binding surface
(Corning Incorporated Life Sciences, Acton, MA), the liposomes
were incubated with aliquots of four different sPLA2 isozymes (Apis Received: September 14, 2001
mellifera (bee) venom, human synovial fluid, Naja naja (cobra) Revised: May 1, 2002
venom, and bovine pancreas (Sigma) and the fluorescence mea- Accepted: May 21, 2002
surement (Molecular Devices Gemini XS, Sunnyvale, CA) was taken
using either scanning, end-point, or kinetic modes. The data were
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